PROMAZINE HYDROCHLORIDE

US Previously Marketed

First approved in 1956

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H20N2S.ClH
Molecular Weight	320.8817
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1c2ccccc2Sc3ccccc31.Cl

InChI

InChIKey=JIVSXRLRGOICGA-UHFFFAOYSA-N

InChI=1S/C17H20N2S.ClH/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19;/h3-6,8-11H,7,12-13H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.4609
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H20N2S
Molecular Weight	284.4208
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/uk/promazine-25mg-tablets-leaflet.html
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00420 | https://www.ncbi.nlm.nih.gov/pubmed/22793499 | https://www.ncbi.nlm.nih.gov/pubmed/2863832 | https://www.ncbi.nlm.nih.gov/pubmed/12084453

Promazine (Sparine) is a phenothiazine neuroleptic used for short-term management of moderate to severe psychomotor agitation and treatment of agitation and restlessness in the elderly. Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tuberoinfundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine. Promazine is not approved for human use in the United States. It is available in the US for veterinary use under the names Promazine and Tranquazine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Histamine H1 receptor 304 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22793499	Antagonist 2575	2.5 µM [IC50]
Serotonin 2 (5-HT2) receptor 83 Target ID: CHEMBL2095200 Sources: https://books.google.ru/books?id=QsofyIjFCeYC&pg=PA548&lpg=PA548&dq=LEVOMEPROMAZINE++5-hydroxytryptamine+receptors&source=bl&ots=ALMCiE6y_d&sig=0aSnEx9jbVLo92LDWIgjdQWzSCE&hl=ru&sa=X&ved=0ahUKEwiP4ejw_4DQAhXBPxoKHUgbDTMQ6AEINjAD#v=onepage&q=LEVOMEPROMAZINE%20%205-hydroxytryptamine%20receptors&f=false	Antagonist 2575
Dopamine receptor 58 Target ID: CHEMBL2096905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6105219	Antagonist 2575	1.0 µM [IC50]
Dopamine D2 receptor 283 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18635692	Antagonist 2575	7.0 null [pKi]
Serotonin 2a (5-HT2a) receptor 211 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18635692	Antagonist 2575	7.9 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Psychomotor agitation 6 Sources: https://www.drugs.com/uk/promazine-25mg-tablets-leaflet.html	Primary		Approved 8043	THORAZINE Approved Use Unknown Launch Date -3.82319985E11
Agitation and restlessness in the elderly 4 Sources: https://www.drugs.com/uk/promazine-25mg-tablets-leaflet.html	Primary		Approved 8043	THORAZINE Approved Use Unknown Launch Date -3.82319985E11

C_max

Value	Dose	Analyte	Population
137 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2265236/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
25 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9869384/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
71.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2265236/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
132.2 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7714731/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
45.7 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7714731/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		PROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1163 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7714731/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
558 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7714731/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
759 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2265236/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
613 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2265236/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Analyte	Population
35.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7714731/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
10.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7714731/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2265236/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
16% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2265236/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	PROMAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
50 mg 1 times / day multiple, oral Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28766806	unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer’s disease Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28766806	Disc. AE: Drug eruption eczematous... AEs leading to discontinuation/dose reduction: Drug eruption eczematous (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28766806
50 mg single, intravenous Dose: 50 mg Route: intravenous Route: single Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/13458245	unhealthy n = 16 Health Status: unhealthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/13458245	Sources: https://pubmed.ncbi.nlm.nih.gov/13458245

AEs

AE	Significance	Dose	Population
Drug eruption eczematous	1 patient Disc. AE	50 mg 1 times / day multiple, oral Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28766806	unhealthy, 79 years n = 1 Health Status: unhealthy Condition: Alzheimer’s disease Age Group: 79 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28766806

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601	substrate 936	substrate 1118

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1330	CYP1A1 325 CYP1A2 972 CYP2A6 485 CYP2B6 616 CYP2C19 910 CYP2E1 606	BCRP 71 MRP2 107

Drug as perpetrator

Target	Modality	Activity
P-gp 1514	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/31640190/	weak [Ki 8.273 uM]
BCRP 713	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	yes
MRP2 434	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/25183402/	yes

Drug as victim

Target	Modality	Activity
CYP1A1 325	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP1A2 972	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP2A6 485	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/ \| https://pubmed.ncbi.nlm.nih.gov/19702528/	yes
CYP2B6 616	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP2C19 910	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP2C9 936	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP2D6 1118	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP2E1 606	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes
CYP3A4 1601	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/12721102/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8459	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8459
ChemicalBook	CB5875452	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5875452
ZINC	ZINC000000010402	http://zinc15.docking.org/substances/ZINC000000010402

PubMed

Title	Date	PubMed
[Acute psychoses caused by digitalis poisoning].	1991 Nov-Dec	1669614
Conventional and atypical antipsychotics in the elderly : a review.	2003	17535043
CSM thioridazine advice.	2004 Aug	15296568
Peroxidase catalysed formation of cytotoxic prooxidant phenothiazine free radicals at physiological pH.	2004 Dec 30	15607761
Substitution and solvent effects on the photophysical properties of several series of 10-alkylated phenothiazine derivatives.	2005 Apr 21	16833671
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.	2005 Dec	16135699
Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.	2005 Jan	15572279
Densitometric high performance thin-layer chromatography identification and quantitative analysis of psychotropic drugs.	2005 Jan-Feb	15759728
Application notes on the use of softer X-rays for anomalous powder diffraction.	2005 Jul	15968118
The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient.	2005 Jul-Aug	15999542
Development and validation of a capillary electrophoresis method for the determination of phenothiazines in human urine in the low nanogram per milliliter concentration range using field-amplified sample injection.	2005 Jun	15924366
Stability of the tranquilizer drug propionylpromazine hydrochloride in formulated products.	2005 Jun	15668921
Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study.	2005 Nov-Dec	16382211
Direct effects of neuroleptics on the activity of CYP2A in the liver of rats.	2005 Nov-Dec	16382210
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.	2005 Sep	18360563
Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action.	2006 Jun	16845229
Interactions of recombinant prions with compounds of therapeutical significance.	2006 Jun 2	16630566
Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine.	2006 Mar	16272405
Use of a fluorescent polarization based high throughput assay to identify new calmodulin ligands.	2006 Nov	17081635
Trypanosoma cruzi dihydrolipoamide dehydrogenase as target for phenothiazine cationic radicals. Effect of antioxidants.	2006 Sep	17017892
Experimental design optimization of a sequential injection method for promazine assay in bulk and pharmaceutical formulations.	2007	18350124
Drug adverse events and drop-out risk: a clinical case.	2007	17317475
The photo comet assay--a fast screening assay for the determination of photogenotoxicity in vitro.	2007 Aug 15	17572134
Amiodarone inhibits tocopherol-mediated human lipoprotein peroxidation.	2007 Jul 15	17531203
Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives.	2007 Mar 1	17188865
QTc and psychopharmacs: are there any differences between monotherapy and polytherapy.	2007 May 3	17477877
The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment.	2007 Sep-Oct	18048963
Neurosyphilis, malaria, and the discovery of antipsychotic agents.	2008	18803105
Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model.	2008 Aug	18423639
Determination of selected phenothiazines in human plasma by solid-phase extraction and liquid chromatography with coulometric detection.	2008 Aug 29	18706338
Capillary electrophoretic separation of tricyclic antidepressants using a polymer-coated capillary and beta-cyclodextrin as an electrolyte additive.	2008 Dec	18985667
Detection of photogenotoxicity in skin and eye in rat with the photo comet assay.	2008 Feb	18264593
Comparative study of the efficiency of synthetic and natural mediators in laccase-assisted bleaching of eucalyptus kraft pulp.	2008 Nov	18499450
The cardiorespiratory effects of a fentanyl infusion following acepromazine and glycopyrrolate in dogs.	2008 Nov 1	19040085
Simultaneous determination of some phenothiazine derivatives in human blood by headspace solid-phase microextraction and gas chromatography with nitrogen-phosphorus detection.	2008 Nov-Dec	19202796
Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.	2008 Oct	19028375
[Determination of antidepressants in biological materials originating from victims of suicide by hanging].	2008 Oct-Dec	19441688
[Application of liquid chromatography coupled with mass spectrometry (LC/MS) to determine antidepressants in blood samples].	2008 Oct-Dec	19441687
P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle.	2008 Sep 23	18759452
Valproate-induced delirium in a demented patient.	2009	19836623
[Drug-induced agranulocytosis--case reports and literature review].	2009	19788146
Rapid method for the determination of tranquilizers and a beta-blocker in porcine and bovine kidney by liquid chromatography with tandem mass spectrometry.	2009 Apr 1	19286028
Plasmids captured in C. metallidurans CH34: defining the PromA family of broad-host-range plasmids.	2009 Aug	19259779
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.	2009 Dec 2	19956587
Acute intoxication by triazolam and promazine: a case report.	2009 Jan	19306624
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.	2009 Jul 14	19597541
Simultaneous chemiluminescence determination of promazine and fluphenazine using support vector regression.	2009 Jul 15	19559917
Validation of derivative spectrophotometry method for determination of active ingredients from neuroleptics in pharmaceutical preparations.	2009 Jul-Aug	19702165
Chemiluminescence determination of promazine in human serum and drug formulations using Ru(phen)3(2+)-Ce(IV) system and a chemometrical optimization approach.	2009 May-Jun	19253268
Structure, function, regulation and polymorphism of human cytochrome P450 2A6.	2009 Sep	19702528

Patents

Sample Use Guides

In Vivo Use Guide

100-200 mg four times daily

Route of Administration: Oral

In Vitro Use Guide

African green monkey kidney cells (Vero 76) were used for activity evaluation. The cells were grown in minimal essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories; Logan UT). For antiviral assays, the serum was reduced to 2% and 50 µg/ml gentamicin added to the medium. Promazine was tested at varying concentrations (four log10 or eight 1/2 log10 dilutions). Virus and compound were added in equal volumes to near-confluent cell monolayers in 96- well tissue culture plates. The multiplicity of infection ranged from 0.001 to 0.004 in order to produce viral cytopathic effects (CPE) for each strain of virus in 100% of the cells in the virus control wells within 3–4 days. The plates were incubated at 37 °C in a 5% CO2 atmosphere until the cells in the virus control wells showed complete viral CPE as observed by light microscopy. Each concentration of drug was assayed for virus inhibition in triplicate and for cytotoxicity in duplicate. Six wells per plate were set aside as uninfected, untreated cell controls and six wells per plate received virus only and represented controls for virus replication. Calpain inhibitor IV was included as positive control drugs

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:09:39 UTC 2021` Edited by `admin` on `Fri Jun 25 21:09:39 UTC 2021`
Record UNII	U16EOR79U4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROMAZINE HYDROCHLORIDE

Common Name

English

PROMAZINE HYDROCHLORIDE [MART.]

Common Name

English

PROMAZINE HCL

Common Name

English

PROMAZINE HYDROCHLORIDE [WHO-DD]

Common Name

English

PROMAZINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

PROMAZINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

10H-PHENOTHIAZINE-10-PROPANAMINE, N,N-DIMETHYL-, MONOHYDROCHLORIDE

Common Name

English

SPARINE

Brand Name

English

PROMAZINE HYDROCHLORIDE [USP]

Common Name

English

PROMAZINE HYDROCHLORIDE [MI]

Common Name

English

PROMAZINE HYDROCHLORIDE [USP-RS]

Common Name

English

10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE MONOHYDROCHLORIDE

Systematic Name

English

PROMAZINE HYDROCHLORIDE [VANDF]

Common Name

English

NSC-17468

Code

English

PROMAZINE HYDROCHLORIDE [GREEN BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710